What Happened?
, -based Candel Therapeutics Promoted Charles Schoch as Interim Chief Financial Officer
About the Company
Also known as Advantagene. Inc., we are a Massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our Gene Mediated Cytotoxic (GMCI™) platform and our rQNestin34.5 platform. GMCI™ is an "off-the-shelf" immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.
About the Person
Charles Schoch is Interim Chief Financial Officer at Candel Therapeutics. Previously, Charles held various senior HR leadership roles in the industry.
Info Source
News
Short Profile